Timely availability and fast access to reliable, high quality tests are essential for healthcare systems.
Thomas Schinecker
Chief Executive Officer of Roche Diagnostics
Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic. Around the world, we are working with urgency, passion and purpose each and every day to deliver high quality tests that are essential for healthcare systems and patients alike.
As a leader in diagnostics testing, we have a responsibility to deliver effective solutions for patients fast. Testing is a critical part in fighting this unprecedented global healthcare emergency and we are proud to be able to contribute.
Real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 in nasal, nasopharyngeal and oropharyngeal swab samples from asymptomatic and symptomatic individuals.
cobas® SARS-CoV-2 & Influenza A/B Test
Simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A virus, and/or influenza B virus in nasal or nasopharyngeal swab samples collected from individuals suspected of a respiratory viral infection consistent with COVID-19 by their healthcare provider.
The Elecsys® SARS-CoV-2 Antigen is an immunoassay for the qualitative detection of the SARS-CoV-2 nucleocapsid antigens.
Authorized for use in screening and testing asymptomatic and symptomatic individuals, cobas® SARS-CoV-2 is a real-time RT-PCR assay intended for the rapid in vitro qualitative detection of SARS-CoV-2.
cobas® SARS-CoV-2 & Influenza A/B Assay
For patients presenting with symptoms of respiratory illness or is suspected of a respiratory infection consistent with COVID-19, the cobas® SARS-CoV-2 & Influenza A/B Assay for use with the cobas® Liat® System brings the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B in an automated multiplex real-time RT-PCR assay for use at the point of care.
The SARS-CoV-2 Rapid Antigen Test is a reliable, rapid chromatographic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx.
SARS-CoV-2 Rapid Antigen Test Nasal
The SARS-CoV-2 Rapid Antigen Test Nasal is a reliable, rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen present in human nasal samples.
SARS-CoV-2 Antigen Self Test Nasal
The SARS-CoV-2 Antigen Self Test Nasal provides reliable results for individuals suspected of having COVID-19. The Self Test can be performed by the general public, providing another option for decentralized testing.
Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2.
Elecsys® Anti-SARS-CoV-2 S is an immunoassay for the in vitro quantitative determination of antibodies (including IgG) to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human serum and plasma.
The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.
The SARS-CoV-2 Rapid Antibody Test is a reliable, rapid chromatographic immunoassay intended for qualitative detection of antibodies (IgM and IgG) to SARS-CoV-2 in human serum, plasma or whole blood.
The test is intended for the use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection.
Because the clinical presentation of COVID-19 and sepsis can be similar, antimicrobial use has increased during the pandemic,1 further driving antimicrobial resistance. Rapid detection or rule-out of bacterial or fungal co-infections and secondary infections can help reduce unnecessary or inadequate antimicrobial therapy.
Reliable diagnostic tests targeting patients that are currently infected by the virus, as well as those that have an immune response against the virus, are valuable. However, it is important to understand which tests are most suitable to use depending on their intended purpose.
*Whether immunity is gained by individuals who have been infected with SARS-CoV-2 is yet to be confirmed due to the novelty of the virus. Data presented here are based on current scientific understanding of the disease (April 2020)
Abbreviations
COVID-19: coronavirus disease 2019
RT-PCR: reverse transcription polymerase chain reaction
